spacer spacer  

This activity is supported by an educational grant from

Daiichi Sankyo
Daiichi-Sankyo logo


Jan N. Basile, MD (Chair)
Chief, Primary Care Service Line
Ralph H. Johnson Veterans Affairs Medical Center
Professor of Medicine
Medical University of South Carolina
Charleston, SC
President, Southern Medical Association
Birmingham, AL

Norman M. Kaplan, MD
Clinical Professor of Medicine
University of Texas
Southwestern Medical Center
Dallas, TX

Thomas D. Giles, MD
Professor of Medicine
Heart and Vascular Institute
Tulane University School of Medicine
New Orleans, LA

Raymond R. Townsend, MD
Professor of Medicine
University of Pennsylvania
Philadelphia, PA


Seventy-three million people in the United States aged 20 and older have high blood pressure (BP) and of that number, 28% do not know they have it. Hypertension (HTN) is a serious cause of cardiovascular disease (CVD), which remains the leading killer of both men and women nationally. In addition, HTN is associated with an increased risk of stroke, congestive heart failure, end-stage renal disease, and other common causes of death. Despite evidence-based treatment guidelines, a wide range of available therapies and national programs to encourage the aggressive detection and management of HTN, BP control remains suboptimal. Selecting the most appropriate antihypertensive drug is multifactorial. In addition to recommending lifestyle modification, physicians must choose between monotherapy, combination therapy, and fixed-dose combination therapy. The mechanisms of action and side effect profiles necessitate consideration in order to optimize therapy. Physicians need to recognize risk factors that put patients with HTN at high risk of CVD and implement early, appropriate therapy to improve patient outcomes and quality of life. This activity will highlight the importance of BP management for patients at high risk of CVD, provide physicians with guideline-directed care, and provide them with an opportunity to apply practical strategies through interactive patient case studies.

Webcast Activity

Introduction and ARS Pre-AssessmentJan N. Basile, MD

Early Appropriate Therapy: Stratifying Risk Factors in Your PatientThomas D. Giles, MD

Guideline Update: Speculations, Revisions, and RecommendationsRaymond R. Townsend, MD

Interactive Case Studies: Designing Tailored Treatment RegimensNorman M. Kaplan, MD

Conclusion, ARS Post-Assessment, and Q&AJan N. Basile, MD

Learning Objectives

Upon the conclusion of this activity, the participant should be able to:

  • RECOGNIZE factors that put patients with HTN at high risk of cardiovascular disease.
  • APPLY clinical guidelines to patient care using efficacy and safety data for current and emerging antihypertensive therapies.
  • SELECT treatment regimens to improve hypertensive management and meet the individual needs of people with HTN.

The American Society of Hypertension, Inc. takes responsibility for the content, quality, and scientific integrity of this CME activity.

Goal & CME Information

GOAL – The goal of this activity is to highlight the importance of BP management for patients at high risk of CVD. We intend to provide physicians with guideline-directed care and the opportunity to apply practical strategies through interactive patient case studies.

INTENDED AUDIENCE – This activity is designed for cardiologists and primary care physicians. No prerequisites required.

ACCREDITATION STATEMENT – The American Society of Hypertension, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT – The American Society of Hypertension, Inc. designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Each physician should claim credit commensurate with the extent of their participation in the activity.

POLICY ON FACULTY AND PROVIDER DISCLOSURE – The American Society of Hypertension, Inc. strives to insure balance, independence, objectivity, and scientific rigor in all of its educational activities. All participants in such activities are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the session in which they are participating. This pertains to relationships, in place at the time of the activity or in the 12 months preceding the activity, with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic.

Jan N. Basile, MD, reports receiving grants/research support from Boehringer Ingelheim, National Heart, Lung, and Blood Institute, and Novartis; serving as a consultant for Abbott Laboratories, Boehringer Ingelheim, Daiichi Sankyo, Inc, Forest Laboratories, Inc, and Novartis; and serving on the speakers’ bureau for Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Inc, Forest Laboratories, Inc, GlaxoSmithKline, Merck & Co, Inc, Novartis, and Pfizer Inc.

Norman M. Kaplan, MD, reports serving as a lecturer for Boehringer Ingelheim.

Thomas D. Giles, MD, reports having no financial or advisory relationships with corporate organizations related to this activity.

Raymond R. Townsend, MD, reports receiving grants/research support from National Institute of Diabetes and Digestive and Kidney Diseases and National Institutes of Health.

OFF-LABEL PRODUCT DISCUSSION – All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

RELEASE DATE – May 31, 2009.    EXPIRATION DATE – May 31, 2011.


ACTIVITY FORMAT – This educational activity is a webcast consisting of approximately 2.0 hours of clinical presentations and question-and-answer sessions.

  • DSL, Cable, or faster Internet connection
  • Internet Explorer 6.0 or newer Web Browser
  • Adobe Flash Player
  • 16-bit sound card
  • 24-bit true color video card
  • Windows 98 or newer
    Pentium or AMD Athlon K6 266 MHz processor or faster
  • Mac OS 9 or later
    PowerPC G3 233MHz processor or faster
  • 128 MB RAM

Step 1. Pre-test

Please complete the Pre-Test Activity before proceeding to the webcast.

Step 2. Webcast

Step 3. Post-test

MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC Contact Us